Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.

These tips can help you better manage MDS fatigue. Myelodysplastic syndromes (MDS) is a type of cancer that shows up as a group of conditions affecting your bone marrow and blood. “Myelo ...

Dr Sanketh K Reddy explains the link between oral cancer and tobacco/alcohol use. He also highlights the symptoms and ...

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS ...

Among treatment naïve (frontline phase 1) HR MDS patients, an ORR of 76% was observed ... Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite ...

I hope in whatever time I have left, be it years, be it months, that I can be bold, even if I some day experience the ...

Hany Elmariah, MD, discusses how he sees fedratinib fitting into clincal practice for the treatment of myeloproliferative neoplasms.

Two early-phase clinical trials demonstrate the safety and potential clinical utility of stem cell therapies to ease motor ...

Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. ( Lancet Oncology) U.S.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...